Editorial
Broader Options for Experimental Clinical Research in Melanoma — Time for Adaptive Platform Trials?
NEJM Evidence · 2024
DOI: 10.1056/evide2400284 ↗Kurz gefasst
Editorial in der Zeitschrift NEJM Evidence, 2024. Verfasst von Thomas A Trikalinos. Beteiligte Einrichtung: Departments of Health Services, Policy, and Practice and Biostatistics, Brown University School of Public Health, Providence, RI. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
MelanomaHumansClinical Trials as TopicSkin NeoplasmsBiomedical ResearchAdaptive Clinical Trials as Topic
Autor:innen und Institutionen
- Departments of Health Services, Policy, and Practice and Biostatistics, Brown University School of Public Health, Providence, RI.
Zitieren
APA
Trikalinos, T. A. (2024). Broader Options for Experimental Clinical Research in Melanoma — Time for Adaptive Platform Trials?. NEJM Evidence. https://doi.org/10.1056/evide2400284
Vancouver
Trikalinos TA. Broader Options for Experimental Clinical Research in Melanoma — Time for Adaptive Platform Trials?. NEJM Evidence. 2024. doi:10.1056/evide2400284
BibTeX
@article{Trikalinos2024,
author = {Trikalinos, Thomas A},
title = {Broader Options for Experimental Clinical Research in Melanoma — Time for Adaptive Platform Trials?},
journal = {NEJM Evidence},
year = {2024},
doi = {10.1056/evide2400284}
}
EUVIMED